NVCT

Kaplan Matthew L.

Known title: DirectorCIK: 0001895952

Kaplan Matthew L.'s purchase track record

Kaplan Matthew L. has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.

PurchaseStockAmount3 months6 months
11/5/2025NVCT$64K+49.7%+77.0%
5/12/2022NVCT$51K-52.2%-60.5%

Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.

Associated companies

AI Market Commentary

AI-generatedAll commentary →

Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.

October 16, 2026

Nuvectis Pharma to speak at Maxim Growth Summit 2026. Nuvectis Pharma announced it will participate in the Maxim Growth Summit 2026. This corporate event provides an opportunity for the company to share updates with investors and analysts. Such appearances are standard for public companies seeking to maintain visibility in the market.

this person other insiders at NVCT

Transaction History

NVCT▲ Buy$0
NVCT▲ Buy$64K
NVCT▲ Buy$0
NVCT▲ Buy$0
NVCT▲ Buy$0
NVCT▲ Buy$19K
NVCT▲ Buy$32K

We use analytics to understand how market-wall is used. No personal data is sold.